Viking Therapeutics, Inc.
VKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001607678
In the last 90 days, Viking Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 437 institutions reported holding it in 13F filings for Q2 2026, worth $2.96B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $6.27M in total
- 3
- 13F holdersQ2 2026, +26 vs. previous quarter
- 437
- 13F valueReported value at the end of Q2 2026
- $2.96B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding VKTX, Q2 2026
No superinvestor reported holding VKTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Viking Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 (view filing)8:07 PM ET | Jul 29 | Same day | Lian BrianPresident & CEO | SSaleCommon Stock, par value $0.00001 per share | −148.5K | $33.32 | −$4.95M | −5.5%2.57M after | |
| Jul 29, 2026 (view filing)8:06 PM ET | Jul 29 | Same day | Zante GregChief Financial Officer | SSaleCommon Stock, par value $0.00001 per share | −21.2K | $33.47 | −$710.1K | −9.1%212.2K after | |
| Jul 29, 2026 (view filing)8:06 PM ET | Jul 29 | Same day | Mancini MariannaChief Operating Officer | SSaleCommon Stock, par value $0.00001 per share | −18.2K | $33.47 | −$609.6K | −4.1%422.8K after | |
| Mar 10, 2026 (view filing) | Mar 10 | Same day | Aubuchon Neil WilliamChief Commercial Officer | PPurchaseCommon Stock, par value $0.00001 per share | +4.47K | $33.50 | +$149.9K | New position4.47K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Zante GregChief Financial Officer | SSaleCommon Stock, par value $0.00001 per share | −57.7K | $32.90 | −$1.90M | −23.3%189.9K after | 4 lots |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Mancini MariannaChief Operating Officer | SSaleCommon Stock, par value $0.00001 per share | −57.7K | $32.97 | −$1.90M | −12.4%409.2K after | 4 lots |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Lian BrianPresident & CEO | SSaleCommon Stock, par value $0.00001 per share | −233.4K | $32.96 | −$7.69M | −8.5%2.50M after | 4 lots |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Foehr Matthew WDirector | SSaleCommon Stock, par value $0.00001 per share | −16.0K | $35.11 | −$561.8K | −10.8%132.0K after | |
| Oct 28, 2025 (view filing) | Oct 28 | Same day | Mancini MariannaChief Operating Officer | SSaleCommon Stock, par value $0.00001 per share | −6.18K | $35.00 | −$216.5K | −1.6%382.5K after | |
| Oct 28, 2025 (view filing) | Oct 27 | 1 day | Rowland Charles A JrDirector | SSaleCommon Stock, par value $0.00001 per share | −60.0K | $35.57 | −$2.13M | −66.7%30.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Viking Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 6,335,756 | $247.2M | 0.01% | +311,003+5.2% | Added |
| BlackRock, Inc. | 6,189,649 | $241.5M | 0.00% | −690,641−10.0% | Reduced |
| State Street Corp | 5,606,394 | $218.7M | 0.01% | +1,210,837+27.5% | Added |
| Vanguard Capital Management LLC | 5,053,663 | $197.1M | 0.00% | +41,161+0.8% | Added |
| Vanguard Portfolio Management LLC | 4,484,263 | $174.9M | 0.01% | +19,965+0.4% | Added |
| Two Sigma Investments, LP | 3,937,414 | $153.6M | 0.12% | −494,728−11.2% | Reduced |
| Morgan Stanley | 3,486,040 | $136.0M | 0.01% | +472,112+15.7% | Added |
| Ameriprise Financial Inc | 2,156,083 | $84.1M | 0.02% | +477,338+28.4% | Added |
| Geode Capital Management, LLC | 2,097,981 | $81.9M | 0.00% | +15,914+0.8% | Added |
| American Century Companies Inc | 1,816,050 | $70.8M | 0.03% | −262,527−12.6% | Reduced |